Table 4.
Best overall response by PD-L1 expression in the injected lesion at baseline by PD-L1 assay and scoring method.
| DAKO CPS | DAKO Mel Score | DAKO TPS | VENTANA SP142 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||||
| Best overall response | <10 | ≥10 | UNK | <1 | ≥1 | UNK | <1% | ≥1% | UNK | <1% | ≥1% | UNK |
|
| ||||||||||||
| All tumor types | N = 38 | N = 30 | N = 48 | N = 14 | N = 22 | N = 70 | N = 40 | N = 39 | N = 27 | N = 14 | N = 10 | N = 82 |
| CR | 0 | 0 | 1 (2.1) | 0 | 0 | 1 (1.4) | 0 | 0 | 1 (3.7) | 0 | 1 (10.0) | 0 |
| PR | 1 (3.6) | 6 (20.0) | 3 (6.2) | 1 (7.1) | 3 (13.6) | 6 (8.6) | 1 (2.5) | 8 (20.5) | 1 (3.7) | 0 | 3 (30.0) | 7 (8.5) |
| SD | 5 (17.9) | 6 (20.0) | 9 (18.8) | 1 (7.1) | 8 (36.4) | 11 (15.7) | 7 (17.5) | 8 (20.5) | 5 (18.5) | 2 (14.3) | 0 | 18 (22.0) |
| NCR/NPD | 0 | 0 | 1 (2.1) | 0 | 0 | 1 (1.4) | 0 | 1 (2.6) | 0 | 0 | 0 | 1 (1.2) |
| PD | 15 (53.6) | 15 (50.0) | 26 (54.2) | 11 (78.6) | 9 (40.9) | 36 (51.4) | 21 (52.5) | 19 (48.7) | 16 (59.3) | 7 (50.0) | 4 (40.0) | 45 (54.9) |
| UNK | 7 (25.0) | 3 (10.0) | 8 (16.7) | 1 (7.1) | 2 (9.1) | 15 (21.4) | 11 (27.5) | 3 (7.7) | 4 (14.8) | 5 (35.7) | 2 (20.0) | 11 (13.4) |
|
| ||||||||||||
| TNBC | N = 10 | N = 8 | N = 5 | N = 0 | N = 0 | N = 23 | N = 11 | N = 8 | N = 4 | N = 10 | N = 10 | N = 3 |
| CR | 0 | 0 | 1 (20.0) | 0 | 0 | 1 (4.3) | 0 | 0 | 1 (25.0) | 0 | 1 (10.0) | 0 |
| PR | 0 | 3 (37.5) | 0 | 0 | 0 | 3 (13.0) | 1 (9.1) | 2 (25.0) | 0 | 0 | 3 (30.0) | 0 |
| SD | 1 (10.0) | 0 | 0 | 0 | 0 | 1 (4.3) | 0 | 1 (12.5) | 0 | 1 (10.0) | 0 | 0 |
| PD | 6 (60.0) | 2 (25.0) | 4 (80.0) | 0 | 0 | 12 (52.2) | 5 (45.5) | 4 (50.0) | 3 (75.0) | 5 (50.0) | 4 (40.0) | 3 (100.0) |
| UNK | 3 (30.0) | 3 (37.5) | 0 | 0 | 0 | 6 (26.1) | 5 (45.5) | 1 (12.5) | 0 | 4 (40.0) | 2 (20.0) | 0 |
|
| ||||||||||||
| Melanoma | N = 14 | N = 19 | N = 5 | N = 12 | N = 21 | N = 5 | N = 6 | N = 14 | N = 18 | N = 0 | N = 0 | N = 38 |
| PR | 1 (7.1) | 2 (10.5) | 0 | 0 | 3 (14.3) | 0 | 0 | 3 (21.4) | 0 | 0 | 0 | 3 (7.9) |
| SD | 3 (21.4) | 6 (31.6) | 3 (60.0) | 1 (8.3) | 8 (38.1) | 3 (60.0) | 2 (33.3) | 6 (42.9) | 4 (22.2) | 0 | 0 | 12 (31.6) |
| PD | 8 (57.1) | 11 (57.9) | 1 (20.0) | 10 (83.3) | 9 (42.9) | 1 (20.0) | 4 (66.7) | 5 (35.7) | 11 (61.1) | 0 | 0 | 20 (52.6) |
| UNK | 2 (14.3) | 0 | 1 (20.0) | 1 (8.3) | 1 (4.8) | 1 (20.0) | 0 | 0 | 3 (16.7) | 0 | 0 | 3 (7.9) |
Note: Data reported as n (%).
Abbreviations: CPS, combined positive score; CR, complete response; Mel, melanoma; NCR/NPD, non-complete response or non-progressive disease; PD, progressive disease; PD-L1, programmed death ligand-1; PR, partial response; SD stable disease; TPS, tumor positive score; UNK, unknown.